It does the job we expected, shipped quickly, and was the best in price compared to competitors.
SML2282
Everolimus
≥95% (HPLC), powder, P-glycoprotein substrate
Everolimus
1 of 1 reviewers took part in a promotion
Synonym(s):
Everolimus, 40-O-(2-Hydroxyethyl)rapamycin, 42-O-(2-Hydroxyethyl)-rapamycin, RAD 001, RAD001, SDZ-RAD, 42-O-(2-Hydroxyethyl)rapamycin
Sign Into View Organizational & Contract Pricing
About This Item
Empirical Formula (Hill Notation):
C53H83NO14
CAS Number:
Molecular Weight:
958.22
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Skip To
Product Name
Everolimus, ≥95% (HPLC)
Quality Level
assay
≥95% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
shipped in
wet ice
storage temp.
−20°C
SMILES string
O=C(C([C@@]1(O)[C@H](C)CC[C@](C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C2=O)([H])O1)=O)N3[C@H](C(O[C@@]([C@@H](C[C@@]4([H])C[C@@H](OC)[C@H](OCCO)CC4)C)([H])CC([C@H](C)/C=C(C)/[C@@H](O)[C@H]2OC)=O)=O)CCCC3
InChI
1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
InChI key
HKVAMNSJSFKALM-GKUWKFKPSA-N
Gene Information
human ... FKBP1A(2280)
Looking for similar products? Visit Product Comparison Guide
Related Categories
1 of 4
This Item | Y0002048 | 94687 | Y0002063 |
|---|---|---|---|
| assay ≥95% (HPLC) | assay - | assay ≥75.0% (qNMR) | assay - |
| form powder | form - | form - | form - |
| storage temp. −20°C | storage temp. −20°C | storage temp. −20°C | storage temp. −20°C |
| solubility DMSO: 2 mg/mL, clear | solubility - | solubility - | solubility - |
| shipped in wet ice | shipped in - | shipped in - | shipped in - |
| color white to beige | color - | color - | color - |
Application
Everolimus has been used as an mechanistic target of rapamycin complex 1 (mTORC1) inhibitor to study its effect on MCF7 and MDA-MB-231 cell lines.[1]
Biochem/physiol Actions
Everolimus, a substrate for P-glycoprotein (P-gp) can be used to treat advanced neuroendocrine tumors (NETs).[2]
Everolimus, the 40-O-(2-hydroxyethyl) derivative of rapamycin (sirolimus), is a potent and selective inhibitor of mechanistic target of rapamycin (mTOR). Everolimus is selective for the mTORC1 protein complex. Everolimus exhibit potent immunosuppressive and anticancer activities.
signalword
Warning
hcodes
Hazard Classifications
Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Repr. 2 - STOT RE 2
target_organs
Kidney,Testes
Storage Class
11 - Combustible Solids
wgk_germany
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Barkovskaya A, et al.
Scientific Reports, 9(1), 5670-5670 (2019)
Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence
Lee L, et al.
Expert Opinion on Pharmacotherapy, 19(8), 909-928 (2018)
Chemical modification of rapamycin: the discovery of SDZ RAD.
R Sedrani et al.
Transplantation proceedings, 30(5), 2192-2194 (1998-09-02)
Matteo Morotti et al.
Nature, 629(8011), 426-434 (2024-04-25)
Expansion of antigen-experienced CD8+ T cells is critical for the success of tumour-infiltrating lymphocyte (TIL)-adoptive cell therapy (ACT) in patients with cancer1. Interleukin-2 (IL-2) acts as a key regulator of CD8+ cytotoxic T lymphocyte functions by promoting expansion and cytotoxic
Heidi A Lane et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(5), 1612-1622 (2009-02-19)
Comparison of the antiangiogenic/vascular properties of the oral mammalian target of rapamycin (mTOR) inhibitor RAD001 (everolimus) and the vascular endothelial growth factor receptor (VEGFR) inhibitor vatalanib (PTK/ZK). Antiproliferative activity against various tumor histotypes and downstream effects on the mTOR pathway
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service